Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Efficacy of oral isotretinoin with intralesional MMR in extragenital cutaneous warts: Patients diagnosed with warts in age group of 14–60 years and having 5 or more warts will
be inclu
group B will receive
intralesional MMR alone. Treatment duration in both groups will be 12 weeks or until clinical resolution, whichever is earlier, and patients will be followed up for 1 month post-
Sponsors
AIIMS Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of warts. 2. Patient having 5 or more warts. 3. Age 14 – 60 years. 4. No topical treatment in last 2 weeks and systemic treatment in previous 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to vaccine or its component or isotretinoin. 2. Pregnant and lactating female. 3. Known case of-HIV, hepatitis B, hepatitis C. 4. Immunocompromised patients. 5. Patient having chronic liver disease, kidney disease or systemic illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare efficacy of oral isotretinoin with intralesional MMR vs intralesional MMR alone in terms of:- 1. Grading of clearance of warts 2. Time needed for complete lesion clearance 3. The number of sessions needed for clearance of all warts completely.Timepoint: Baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks and 4 weeks post treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Recurrence rate 2. Patient satisfaction score 3. DLQI (Dermatology life quality index) 4. To compare side effects profile of two groups.Timepoint: Baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks and 4 weeks post treatment | — |
Countries
India
Contacts
Public ContactSaurabh Kushwaha
AIIMS JODHPUR
Outcome results
None listed